Table 5:

Success rates of chronic FDA targeting: recorded neurons per session

Animal	PPT	LDT	DR	VLPO	LC
1			[6, 2, 3, 4, 2, 3, 3, 4, 8, 5, 1, 3, 3] (3.61 ± 1.85)
2
3	[4, 2, 5, 6, 6, 8, 11, 7, 9, 5, 4, 8] (6.25 ± 2.49)		[6, 2, 4, 6, 6, 5, 5, 3, 2, 1, 2, 1] (3.58 ± 1.97)
4	[5, 6, 7, 5, 8, 7, 7, 6, 7] (6.44 ± 1.01)		[2, 4, 2, 2, 2, 1, 0, 2, 3] (2 ± 1.11)
5	[0, 0, 2, 0, 0, 1, 0, 0, 0, 1, 1, 2] (0.58 ± 0.79)		[1, 2, 3, 2, 3, 2, 0, 1, 1, 0, 0, 3] (1.5 ± 1.16)
6	[0, 0, 0, 0, 1, 3, 4, 4, 3, 5] (2 ± 2)	[0, 0, 0, 2, 2, 1, 3, 3, 1, 2] (1.4 ± 1.17)	[1, 3, 3, 2, 3, 3, 4, 3, 4, 1] (2.7 ± 1.05)
7	[4, 3, 3, 2, 3, 4, 2, 3] (3 ± 0.76)	[5, 2, 3, 4, 5, 4, 2, 4] (3.62 ± 1.88)	[5, 5, 4, 3, 5, 4, 2, 4] (4 ± 1.07)	[6, 3, 3, 4, 4, 2, 1, 3] (3.25 ± 1.49)
8	[0, 2, 2, 1, 0, 0, 1] (0.85 ± 0.9)	[0, 0, 6, 3, 4, 3, 3] (2.71 ± 2.14)	[0, 0, 1, 0, 1, 1, 0] (0.43 ± 0.53)	[3, 2, 3, 1, 0, 0, 0] (1.28 ± 1.38)
9	Kinked	[6, 7, 5, 6, 5, 5, 4, 6, 3] (5.22 ± 1.2)	[1, 1, 4, 7, 6, 6, 8, 5, 6] (4.88 ± 2.47)	[0, 0, 0, 0, 0, 0, 0, 0, 0]
10	[0, 0, 0, 0, 4, 0, 0, 3, 1] (0.88 ± 1.53)	[6, 5, 3, 4, 8, 3, 3, 7, 4] (4.77 ± 1.85)	[0, 2, 3, 0, 5, 3, 4, 2, 4] (2.56 ± 1.74)	[6, 1, 2, 0, 2, 1, 1, 0, 0] (1.44 ± 1.87)
11	[1, 7, 8, 4, 6, 6, 3, 7] (5.25 ± 2.37)	Kinked	[5, 3, 0, 0, 0, 0, 3, 4] (1.87 ± 2)	[1, 2, 5, 3, 2, 3, 0, 0] (2 ± 1.69)
12	[5, 2, 3, 3, 3, 3, 2, 4] (3.12 ± 0.99)	[5, 3, 3, 3, 5, 2, 5, 4] (3.75 ± 1.16)	[0, 0, 0, 0, 0, 0, 0, 0]	[5, 3, 2, 3, 0, 0, 2, 1] (2 ± 1.69)
13	[6, 6, 5, 3, 5, 5] (5 ± 1.09)	[0, 4, 6, 3, 1, 2] (2.66 ± 2.16)	Kinked	[2, 3, 2, 1, 0, 0] (1.33 ± 1.21)	[2, 0, 0, 2, 0, 0] (0.67 ± 1.03)

Number of neurons recorded from each target per recording session, unless the axis was kinked or each session had zero neurons: [no. of neurons per session] (mean ± SD). Each recording session occurred after one or more axis was moved forward during a driving session. The units included were stable for at least three days during continuous recording periods.